REG - Scancell Holdings - Director Dealing

Scancell HoldingsAnnouncement

16/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250916:nRSP4073Za&default-theme=true

RNS Number : 4073Z  Scancell Holdings Plc  16 September 2025

16 September 2025

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Director Dealing

 

Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and
Moditope® active immunotherapies to treat cancer, announces that Vulpes
Testudo Fund, a fund closely associated with Martin Diggle, Non-Executive
Director, has purchased 3,150,000 ordinary shares of 0.1p each ('Ordinary
Shares') in the Company on 12 September 2025 at a price of 8.861 pence per
share. Following the purchase, Vulpes Life Science Fund and Vulpes Testudo
Fund together hold 143,537,037 ordinary shares representing 13.83% of the
company.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

 

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Vulpes Testudo Fund
 2   Reason for the notification
 a)  Position/status                                              Fund closely associated with Martin Diggle, Non-Executive Director
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Scancell Holdings plc
 b)  LEI                                                          2138008RXEG856SNP666
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence each
 b)  Identification Code                                          GB00B63D3314
 c)  Nature of the transaction                                    Purchase of Ordinary Shares

 d)  Price(s) and volume(s)                                       8.861 pence and 3,150,000
 e)  Aggregated information

     - Aggregated volume                                          3,150,000 Ordinary Shares

     - Price                                                      8.861 pence per Ordinary Share
 f)  Date of the transaction (s)                                  12 September 2025
 g)  Place of the transaction                                     London Stock Exchange, AIM

 

-ENDS-

Scancell (LSE:SCLP; www.scancell.co.uk (http://www.scancell.co.uk) ) is a
clinical stage biotechnology company developing targeted off-the-shelf active
immunotherapies, to generate safe and long-lasting tumour-specific immunity
for a cancer-free future. iSCIB1+, the lead product from their DNA
ImmunoBody® platform has demonstrated safe, durable and clinically meaningful
benefit as a monotherapy as well as additional benefit when combined with
checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead
peptide immunotherapy from their Moditope® platform, is being investigated in
a Phase 2 study in a broad range of solid tumours. In addition, Scancell's
wholly owned subsidiary, GlyMab Therapeutics Ltd., has been established with
the intention to hold and develop an exciting early-stage pipeline of high
affinity GlyMab® antibodies targeting tumour specific glycans, two of which
already have been licensed and are being developed by Genmab A/S, an
international biotechnology company and global leader in the antibody
therapeutics space.

For more information please contact:

 Scancell Holdings plc                                   +44 (0) 20 3709 5700
 Phil L'Huillier, CEO
 Sath Nirmalananthan, CFO

 Panmure Liberum (Nominated Adviser and Joint Broker)    +44 (0) 20 7886 2500
 Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                          +44 (0) 20 3705 9330

 David Wilson, Claes Spang

 Investor and media relations                            +44 (0) 20 7483 284853

 Mary-Ann Chang                                          MaryAnnChang@scancell.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSFEFMIEISEEU